The AVMA Group Health and Life Insurance Trust (GHLIT) recently sent a letter to its medical insurance participants indicating that New York Life Insurance Company (NYL), the underwriter for the GHLIT, intends to discontinue offering medical insurance coverage in the bona fide association market at the end of next year. As a result, GHLIT medical insurance coverage for AVMA members will be ending one year from now, effective midnight Dec. 31, 2013.
The GHLIT is deeply saddened by this decision, as we know how important medical insurance is for you and your family. If you’re affected by the NYL decision, you undoubtedly have questions. GHLIT has posted numerous resources on its website for your information; including the letter explaining NYL’s decision, answers to frequently asked questions and a press release.
The GHLIT has offered medical insurance coverage exclusively to AVMA members for over 56 years. In an effort to maintain medical coverage for these valued AVMA members and their families, the GHLIT and the AVMA’s Governmental Relations Division worked extensively over the past year with the Department of Health and Human Services and key Congressional offices to try to preserve bona fide association medical plans like ours. Unfortunately, due to changes that are coming into effect because of the health care reform law, NYL determined that it would be unable to continue to offer competitive medical insurance coverage for association plans such as the GHLIT’s.
We understand the significance of this change and the confusion it may create. Be assured that the GHLIT remains dedicated to your protection and is working with its business partners to establish a program to help assist you with the transition to other medical insurance coverage in 2014. We will have more information in the coming weeks and will continue to communicate with GHLIT members who are affected on a regular basis.
Please contact the GHLIT at 800-621-6360 if you have any questions or concerns.
Thank you for your understanding and your patience.